Citius pharmaceuticals, inc. reports fiscal first quarter 2024 financial results and provides business update

Resubmitted lymphir™ biologics license application; awaiting pdufa date completed enrollment in the mino-lok® pivotal phase 3 trial cranford, n.j. , feb. 14, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius" or the "company") (nasdaq: ctxr), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal first quarter 2024 ended december 31, 2023.
CTXR Ratings Summary
CTXR Quant Ranking